Suppr超能文献

[良性前列腺增生症的药物治疗]

[Pharmacotherapy in benign prostatic hyperplasia].

作者信息

Hauri D

机构信息

Urologische Klinik, Universitätsspital Zürich.

出版信息

Ther Umsch. 1995 Jun;52(6):378-82.

PMID:7541566
Abstract

To avoid an operation, there are innumerable pharmaceutics on sale for the treatment of the benign prostatic hyperplasia. For this reason we have to distinguish between pharmaceutics without effect and those with proved action on the hyperplastic metaplasia. The symptoms can often be lessened at the initial stage by way of drugs with ineffective action (phytopharmaceutics); there could not yet be proved any effect on the biology of the prostatic hyperplasia. We make use of this therapeutic at the initial stage. Some of the substances with a real effect (alpha-receptor blockers, alpha-reductase inhibitors) do not necessarily provide an effective result in all cases. In addition to that, these therapeutics of partially serious side effects have to be taken for life. Here immediately arises the question of how it could be managed financially.

摘要

为避免手术,市面上有无数治疗良性前列腺增生的药物在售。因此,我们必须区分无效药物和对增生性化生有确切疗效的药物。在初始阶段,症状通常可通过无实际疗效的药物(植物药)得以缓解;尚未证实其对前列腺增生生物学有任何作用。我们在初始阶段采用这种疗法。一些有实际疗效的药物(α受体阻滞剂、α还原酶抑制剂)并非在所有情况下都能产生有效结果。除此之外,这些有部分严重副作用的疗法必须终身服用。这里马上就出现了费用如何解决的问题。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验